NHIA expands access to atopic dermatitis treatment
NHIA expands access to atopic dermatitis treatment
2026-07-17
Taiwan’s National Health Insurance Administration is expanding access to treatment for people living with atopic dermatitis. After broadening reimbursement criteria over the past few years, it has now added a newly-approved biologic to the reimbursement program. More than 1,000 patients suffering from moderate to severe symptoms are expected to benefit. Let’s hear more.
Yen Chia-jui
National Health Insurance Administration
Atopic dermatitis is a condition that persists for a long time. As part of our resource allocation plans, we at the National Health Insurance Administration have been expanding our reimbursement policy. Back on Feb. 1, 2024, we expanded the coverage of biologic therapies to include children as young as 6, down from the previous age restriction of 12 and up. Starting June 1 this year, a newly-approved biologic medication was added to the reimbursement list. And coverage has been expanded to two years, instead of being limited to one year.
Alice
Has atopic dermatitis
The new biologic medication made almost all of my visible flare-ups go away. My skin is finally smooth and clear again.
Atopic dermatitis is a chronic condition that often returns with severe flare-ups, leaving many patients struggling with years of physical discomfort and emotional stress. Health officials say the newly expanded coverage marks a major milestone in treatment, with reimbursement now available for up to two years instead of one. The policy is expected to benefit around 1,108 patients. That includes people with chronic moderate to severe atopic dermatitis whose symptoms have persisted for at least six months.
For more Taiwan news, tune in:
Mon to Fri at 9:30 pm on Channel 152
Tue to Sat at 1 am on Channel 53
#atopicdermatitits #dermatitis #goodnews #health #medicine
異位性皮膚炎"迎曙光! 新型生物製劑納健保給付
2026-07-17
健保署近年逐步放寬，異位性皮膚炎相關藥物的給付標準，現在又有新型生物製劑納入健保給付，預計有上千位，中重度病友能受惠。
[[健保署副署長 顏家瑞]]
“這個病會困擾病友很久，健保在財源的規劃下，我們初步放寬給付的標準，包括從民國113年開始，2月1日我們就放寬生物製劑的給付，把年齡放寬到6歲以下，本來只有在12歲。從今年6月1日開始，有一個新生物製藥，那我們也透過公平會的決議，開始可以給付給病友，藥物給付是兩年，不再限縮在以前的一年”
[[中重度異位性皮膚炎病友 Alice]]
“新型的生物製劑的治療方式，可以讓我的外顯的病灶幾乎都可以消失，甚至皮膚可以恢復到光滑平整的樣子”
異位性皮膚炎很容易反覆急性復發，是無數病友難以擺脫的身心折磨，現在迎來治療新里程，健保署宣布新型生物製劑，開始納入健保給付，藥物給付期間為2年，預估受惠人數可達1108人，對象主要是針對慢性中重度異位性皮膚炎病友，且病灶需要持續至少6個月，希望持續提供病友，更優質的醫療照顧。
更多新聞內容，請鎖定：
民視台灣台（152頻道）週一至週五晚上9:30
民視新聞台（53頻道）週二至週六凌晨1:00
Related News
